Eylea market is driven by factors such as growing partnerships and collaborations are expected to grow at a CAGR of 4.20% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Eylea Market” that contains information from 2018 to 2032.TheEylea market is estimated to register a CAGR of 4.20% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global Eylea market— Regeneron Pharmaceuticals, Inc., Bayer AG, Novartis International AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Roche Holding AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, GlaxoSmithKline plc.

Market Highlights

The global eylea market is accounted to register a CAGR of 4.20% during the forecast period and is estimated to reach USD 10.9 billion by 2032.

A significant portion of the elderly population gets dry AMD. Nonetheless, there are noteworthy instances of wet AMD. Due of the high percentage of people worldwide who suffer from diabetes, the eylea market is expanding rapidly. Diabetic retinopathy is a complex retinal disorder mostly caused by elevated blood sugar levels, and diabetes is one of the main causes of it. A growing percentage of working women and stressful work environments have led to a greater emphasis on ready-to-eat meals, which has increased the incidence of diabetes and driven market expansion.

Segment Analysis

The global eylea market has been segmented based Product, and Application.

On the basis of Product, the market is segmented into Prefilled Syringe Package, and Vial Package. The prefilled syringe package segment was attributed to holding the largest market share in 2022, due to evolving regulations and increasingly complex medication administration methods.

Based on Application, the global Eylea market has been segmented into Hospitals, Retail Pharmacy, and Others. The hospitals segment was expected to hold the largest market share in 2022. This is due to rising frequency of patients with diabetic retinopathy, wet age-related macular degeneration (AMD), and other retinal conditions that need medical professionals' attention for appropriate treatment.

Regional Analysis

The global Eylea market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Eylea market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Eylea market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Eylea market comprises of Middle East, Africa, and Latin America.

The largest market share for Eylea was maintained by the North American regional sector. The need for efficient treatment options, like Eylea, is fueled by the increasing prevalence of retinal illnesses in North America, including wet AMD, DME, and RVO. Wet AMD is one of the age-related eye disorders that more often affects the elderly population. Treatments like Eylea, which is frequently used in the senior population, are becoming more and more necessary as the population ages.

Moreover, the Europe market has been persistently growing over the forecast period. Diabetic macular edema is more common in Europe due in part to the rising prevalence of diabetes. Eylea's use is being driven by the increasing number of patients, as it is indicated for the treatment of DME. The market growth of Eylea is attributed to regulatory approvals for the treatment of various retinal diseases and the expansion of its indications. Healthcare professionals can now utilize Eylea for a wider variety of patients thanks to expanded permissions.

Additionally, the incidence of age-related eye disorders is higher in an aging population. The Asia-Pacific area is witnessing a rise in demand for treatments tailored to the unique requirements of the elderly population. Diabetic macular edema is more common in the Asia-Pacific region due to the growing prevalence of diabetes. Diabetes is a primary risk factor for retinal illnesses; hence there will likely be an increase in demand for medications like Eylea.

Furthermore, the rest of the world's Eylea market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's rising investments in research and development. Government support, a rise in investor interest, and the viability of the technology in the sector are all contributing factors to the market expansion.

Key Findings of the Study

• The global Eylea market is expected to reach USD 10.9 billion by 2032, at a CAGR of 4.20% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the growing prevalence of diabetes.


• Based on Application, the Hospitals segment was attributed to holding the largest market in 2022.


• Regeneron Pharmaceuticals, Inc., Bayer AG, Novartis International AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Roche Holding AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, GlaxoSmithKline plc.